Contact

It's the GeneMedi's summary page for Target/Biomarker Introduction of CD20,MS4A1. The page also collects GeneMedi's different modalities and formats products for CD20 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the CD20 target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

This gene encodes a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. This gene encodes a B-lymphocyte surface molecule which plays a role in the development and differentiation of B-cells into plasma cells. This family member is localized to 11q12, among a cluster of family members. Alternative splicing of this gene results in two transcript variants which encode the same protein. [provided by RefSeq, Jul 2008]

Target IDGM-T73215
Target NameCD20
Gene ID931
Gene Official NameMS4A1
Gene AliasB1, Bp35, CD20, CVID5, LEU-16, MS4A2, S7
Protein Sub-locationTransmembrane Protein
CategoryTherapeutics Target, INN Index, Immuno-oncology Target


Pre-made CD20-specific INN-index biosimilar (antibody&conjugates)-Mosunetuzumab, Obinutuzumab, ibritumomab tiuxetan, Eramkafusp, Divozilimab, Odronextamab, Ocaratuzumab, Glofitamab, Plamotamab, Veltuzumab, Zuberitamab, eramkafusp alfa, Ofatumumab, Epcoritamab, Ocrelizumab, Afutuzumab, Blontuvetmab, technetium (99mTc) nofetumomab merpentan, tositumomab, Ublituximab, Ripertamab, Rituximab, epitumomab

Anti-CD20 therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cat No.Products Name (INN Index)INN Name Previous Name Target FormatOrder
GMP-Bios-ab-356Pre-Made Mosunetuzumab biosimilar, Bispecific mAb, Anti-CD3E;MS4A1/CD20 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibodyMosunetuzumabCD3E;MS4A1/CD20Bispecific mAbINN mab
GMP-Bios-ab-385Pre-Made Obinutuzumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibodyObinutuzumabAfutuzumabMS4A1/CD20Whole mAbINN mab
GMP-Bios-INN-859Pre-Made Ibritumomab Tiuxetan Biosimilar, Radiolabelled Antibody, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibodyibritumomab tiuxetanMS4A1/CD20Radiolabelled antibodyINN mab
GMP-Bios-ab-192Pre-Made Eramkafusp biosimilar, Whole mAb Fusion, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibodyEramkafuspMS4A1/CD20Whole mAb FusionINN mab
GMP-Bios-ab-149Pre-Made Divozilimab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibodyDivozilimabMS4A1/CD20Whole mAbINN mab
GMP-Bios-ab-391Pre-Made Odronextamab biosimilar, Bispecific mAb, Anti-MS4A1/CD20;CD3E Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7;T3E/TCRE/IMD18 therapeutic antibodyOdronextamabMS4A1/CD20;CD3EBispecific mAbINN mab
GMP-Bios-ab-387Pre-Made Ocaratuzumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibodyOcaratuzumabMS4A1/CD20Whole mAbINN mab
GMP-Bios-ab-248Pre-Made Glofitamab biosimilar, Bispecific mAb with Domain Crossover, Anti-CD3E;MS4A1/CD20 antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7therapeutic antibodyGlofitamabCD3E;MS4A1/CD20Bispecific mAb with Domain CrossoverINN mab
GMP-Bios-ab-446Pre-Made Plamotamab biosimilar, Bispecific Mixed mAb and scFv, Anti-MS4A1/CD20;CD3E Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7;T3E/TCRE/IMD18 therapeutic antibodyPlamotamabMS4A1/CD20;CD3EBispecific Mixed mAb and scFvINN mab
GMP-Bios-ab-617Pre-Made Veltuzumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibodyVeltuzumabMS4A1/CD20Whole mAbINN mab
GMP-Bios-ab-651Pre-Made Zuberitamab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibodyZuberitamabMS4A1/CD20Whole mAbINN mab
GMP-Bios-INN-843Pre-Made Eramkafusp Alfa Biosimilar, Fusion Protein targeting MS4A1/CD20 fused with human IFNA2 (interferon alpha 2) via a peptidyl linker: Recombinant therapeutic protein targeting B1/Bp35/CVID5/FMC7/LEU-16/S7eramkafusp alfaMS4A1/CD20Fusion ProteinINN mab
GMP-Bios-ab-392Pre-Made Ofatumumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibodyOfatumumabMS4A1/CD20Whole mAbINN mab
GMP-Bios-ab-189Pre-Made Envafolimab biosimilar, Single Domain Variable Fragment;H, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PD-L1/PDCD1L1/PDCD1LG1/PDL1/hPD-L1 therapeutic antibodyEpcoritamabCD3E;MS4A1/CD20Bispecific mAbINN mab
GMP-Bios-ab-389Pre-Made Ocrelizumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibodyOcrelizumabMS4A1/CD20Whole mAbINN mab
GMP-Bios-ab-013Pre-Made Afutuzumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibodyAfutuzumabObinutuzumabMS4A1/CD20Whole mAbINN mab
GMP-Bios-ab-075Pre-Made Blontuvetmab biosimilar, Canine Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibodyBlontuvetmabMS4A1/CD20Canine Whole mAbINN mab
GMP-Bios-INN-1012Pre-Made Technetium (99Mtc) Nofetumomab Merpentan Biosimilar, Radiolabelled Antibody: Anti-MS4A1/CD20 therapeutic antibodytechnetium (99mTc) nofetumomab merpentanMS4A1Radiolabelled antibodyINN mab
GMP-Bios-INN-1028Pre-Made Tositumomab Biosimilar, Radiolabelled Antibody, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibodytositumomabMS4A1/CD20Radiolabelled antibodyINN mab
GMP-Bios-ab-598Pre-Made Ublituximab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibodyUblituximabMS4A1/CD20Whole mAbINN mab
GMP-Bios-ab-485Pre-Made Ripertamab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibodyRipertamabMS4A1/CD20Whole mAbINN mab
GMP-Bios-ab-487Pre-Made Rituximab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibodyRituximabMS4A1/CD20Whole mAbINN mab
GMP-Bios-INN-838Pre-Made Epitumomab Biosimilar, Whole Mab, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibodyepitumomabMS4A1/CD20Whole  mAbINN mab



Pre-made anti-CD20 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-CD20 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-CD20 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cat No.Antibody NameFormatClassified by tagOrder
GM-Tg-hg-T73215-AbAnti-CD20/MS4A1 monoclonal antibodymabBiofunctional antibody, Therapeutics Target antibodymonoclonal antibody.




GENEMEDI
6th Floor, Building No.2, Kangxin Road 3377, Shanghai, China
Email: [email protected]   [email protected]
Telephone: +86-21-50478399   Fax: 86-21-50478399
Privacy Policy
Chinese Website

Apply for
Free
Sample

Sample FOC application

×